The finding that ER, PR and HER2 status was available in less than 50% of the study population highlights the potential for chemotherapy overtreatment in patients with early stage breast cancer and a missed opportunity to identify patients with triple-negative breast cancer linked to an increased risk of harboring pathogenic BRCA1 mutations (Chen et al., 2018). Here, BRCA1 is linked to breast carcinoma.